Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius
about
Purification, properties, and characterization of recombinant Streptomyces sp. strain C5 DoxA, a cytochrome P-450 catalyzing multiple steps in doxorubicin biosynthesisDoxorubicin overproduction in Streptomyces peucetius: cloning and characterization of the dnrU ketoreductase and dnrV genes and the doxA cytochrome P-450 hydroxylase gene.In vivo and in vitro bioconversion of epsilon-rhodomycinone glycoside to doxorubicin: functions of DauP, DauK, and DoxAIsolation and characterization of a gene from Streptomyces sp. strain C5 that confers the ability to convert daunomycin to doxorubicin on Streptomyces lividans TK24Identification of NAD(P)H Quinone Oxidoreductase Activity in Azoreductases from P. aeruginosa: Azoreductases and NAD(P)H Quinone Oxidoreductases Belong to the Same FMN-Dependent Superfamily of EnzymesChemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of actionMolecular cloning and characterization of the aklavinone 11-hydroxylase gene of Streptomyces peucetius subsp. caesius ATCC 27952The Streptomyces peucetius dpsY and dnrX genes govern early and late steps of daunorubicin and doxorubicin biosynthesisSulforaphane prevents doxorubicin-induced oxidative stress and cell death in rat H9c2 cellsA unique carrier for delivery of therapeutic compounds beyond the blood-brain barrierDietary red palm oil protects the heart against the cytotoxic effects of anthracyclineDrug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin.A note from history: Landmarks in history of cancer, part 7.Identification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis.Doxorubicin, DNA torsion, and chromatin dynamics.Fabrication of graphene-isolated-Au-nanocrystal nanostructures for multimodal cell imaging and photothermal-enhanced chemotherapy.Anthracycline cardiotoxicity: prevalence, pathogenesis and treatmentNicotinamide-mediated inhibition of SIRT1 deacetylase is associated with the viability of cancer cells exposed to antitumor agents and apoptosis.Clinical significance of ischemia-modified albumin in the diagnosis of doxorubicin-induced myocardial injury in breast cancer patients.Doxorubicin pathways: pharmacodynamics and adverse effects.Targeted albumin-based nanoparticles for delivery of amphipathic drugs.Application of silver N-heterocyclic carbene complexes in O-glycosidation reactionsA comprehensive review of glycosylated bacterial natural products.Cloning and expression of daunorubicin biosynthesis genes from Streptomyces peucetius and S. peucetius subsp. caesiusAssociation of ABCB1 and SLC22A16 Gene Polymorphisms with Incidence of Doxorubicin-Induced Febrile Neutropenia: A Survey of Iranian Breast Cancer PatientsDrug-induced mitochondrial dysfunction and cardiotoxicity.Synthesis and DNA-binding affinity studies of glycosylated intercalators designed as functional mimics of the anthracycline antibioticsStrategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.Taxonomy, Physiology, and Natural Products of Actinobacteria.A study on the toxic effects of Doxorubicin on the histology of certain organs.Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.David and Goliath: chemical perturbation of eukaryotes by bacteria.Cancer nanomedicines: so many papers and so few drugs!Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity.Metabologenomics: Correlation of Microbial Gene Clusters with Metabolites Drives Discovery of a Nonribosomal Peptide with an Unusual Amino Acid MonomerChlorizidine, a cytotoxic 5H-pyrrolo[2,1-a]isoindol-5-one-containing alkaloid from a marine Streptomyces sp.Anthracycline Nano-Delivery Systems to Overcome Multiple Drug Resistance: A Comprehensive Review.Ikaros expression sensitizes leukemic cells to the chemotherapeutic drug doxorubicinMaximizing the Benefit-Cost Ratio of Anthracyclines in Metastatic Breast Cancer: Case Report of a Patient with a Complete Response to High-Dose Doxorubicin.High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin.
P2860
Q24516813-156AB2E6-9E0A-4F18-9D33-7CCA7AF7DE25Q24516817-C5508749-C5D7-4962-A982-A38AE67F6F3CQ24678978-76DD0F2C-FF9B-4305-BAE2-80555EE4DB5EQ24683662-BB83241A-287F-4EB2-A404-EC0CA1BC500AQ27684286-E6C92E83-7417-45E7-BB62-2C1E1AE50E41Q27693179-07C22085-AFCC-4914-84DD-F96336DBDBFFQ28369069-1928129A-E0C7-4B70-848A-4F1CACF9FE90Q28379486-98A94FF0-B8CD-44A9-8988-E01C3FEA74DFQ28397899-E44A36DE-0480-44B5-8883-930DA4DB2D02Q28472987-2CFB0DE8-D115-4C18-B5F6-DC63C36CE332Q28583225-F8FFE3BB-5997-44C2-AC8F-FDB9DFC702C6Q30540353-70EECFE0-D857-4119-99CC-29558580A5EFQ30931923-851B7707-7B50-40F8-A5E1-F8FB0403EFACQ33653056-44A82F96-957B-44AF-ABB6-C8FCD624FEF9Q34039414-778AE15E-E176-467B-A12A-32DFB6999B71Q34117057-FDCFCD6C-9643-4FFF-8C07-7A90993C02E3Q34639876-45865831-70D8-4674-9276-C76268AC260BQ35020234-8AA8BE9D-FA3D-41CA-A24E-D2C7B6FD6FF6Q35041318-181EF8AA-698C-4B54-B7F0-BE25F14879B8Q35048393-902B9D2D-D96D-49D4-8C45-210C716FCEE4Q35086678-6B2CA1C6-8848-461E-A6C6-BBCA0FCC648EQ35545551-B7558127-A30C-40A8-883F-1E5CED2F2456Q36029831-D865DA7A-1D29-491B-9B50-1A14B9649FC2Q36165429-BC90EBB0-18E9-43E6-8ADD-3B7EBC5309B9Q36236476-5C3FD498-F68A-4B6B-82D5-E94C183D7541Q36339445-1460D2D6-D651-47F0-90A5-415919A53323Q36345568-7724DCCC-D32B-439B-AAA0-A4B3656B4DDFQ36372894-E300255D-F30E-4C69-B4C1-0C0BA911C142Q36457919-B5EDF5B9-3A87-4E59-9154-882AF4C8B9C6Q36495358-FDE1CEEC-CE2A-4B65-AB36-D9CB590D5B5BQ36568908-81DA8269-40A5-4876-B400-6AEA7647ACAEQ36577080-505BDC33-E029-4378-BDBC-BB0BCEA5E9C0Q36589023-4B0590E5-AC2B-4BA5-83F6-2DF2EBABF3EFQ36637796-4EC4BDD0-2E28-4036-AC1C-897BF2567038Q36787154-2BE0504B-7AD5-4A6F-B24E-D3185D6EA855Q36984688-ED7824BB-1AC6-4959-8D0B-71AA8EF25D88Q37031597-7108B76D-99FB-4335-B866-F7BD2860496DQ37106766-E0906E07-EB43-49A2-AF21-DBA85C7E4985Q37563014-A3922333-61C0-482E-B529-21FD69760849Q37695195-0E19C6AA-65ED-44AA-A212-F3FB74417366
P2860
Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius
description
1969 nî lūn-bûn
@nan
1969 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1969 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1969年の論文
@ja
1969年論文
@yue
1969年論文
@zh-hant
1969年論文
@zh-hk
1969年論文
@zh-mo
1969年論文
@zh-tw
1969年论文
@wuu
name
Adriamycin, 14-hydroxydaunomyc ...... from S. peucetius var. caesius
@ast
Adriamycin, 14-hydroxydaunomyc ...... from S. peucetius var. caesius
@en
Adriamycin, 14-hydroxydaunomyc ...... from S. peucetius var. caesius
@nl
type
label
Adriamycin, 14-hydroxydaunomyc ...... from S. peucetius var. caesius
@ast
Adriamycin, 14-hydroxydaunomyc ...... from S. peucetius var. caesius
@en
Adriamycin, 14-hydroxydaunomyc ...... from S. peucetius var. caesius
@nl
prefLabel
Adriamycin, 14-hydroxydaunomyc ...... from S. peucetius var. caesius
@ast
Adriamycin, 14-hydroxydaunomyc ...... from S. peucetius var. caesius
@en
Adriamycin, 14-hydroxydaunomyc ...... from S. peucetius var. caesius
@nl
P2093
P356
P1476
Adriamycin, 14-hydroxydaunomyc ...... from S. peucetius var. caesius
@en
P2093
F Arcamone
G Cassinelli
P304
P356
10.1002/BIT.260110607
P407
P577
1969-11-01T00:00:00Z